Market Inference Reports -- FMS Stock

Shares of Fresenius Medical Care have moved 11.7% today, and are now trading at a price of $20.85. In contrast, the S&P 500 index saw a -1.0% change. Today's trading volume is 396,238 compared to the stock's average volume of 404,761.

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. Based in Bad Homburg, Germany the company has 119,845 full time employees and a market cap of $12,613,664,768. Fresenius Medical Care currently offers its equity investors a dividend that yields 6.4% per year.

The company is now trading 7.7% away from its average analyst target price of $19.36 per share. The 4 analysts following the stock have set target prices ranging from $15.01 to $24.01, and on average give Fresenius Medical Care a rating of underperform.

Over the last 12 months FMS shares have declined by -1.9%, which represents a difference of -30.6% when compared to the S&P 500. The stock's 52 week high is $27.72 per share and its 52 week low is $16.37. With its net margins declining an average -27.7% over the last 5 years, Fresenius Medical Care declining profitability gives us reason to believe its stock price will continue to underwhelm.

Date Reported Total Revenue ($ k) Net Profit ($ k) Net Margins (%) YoY Growth (%)
2023 4,936,237 84,351 2 -33.33
2022 19,398,017 673,405 3 -50.0
2021 17,618,685 969,308 6 -14.29
2020 17,859,063 1,164,377 7 0.0
2019 17,476,555 1,199,619 7 -41.67
2018 16,546,873 1,981,924 12 n/a
The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.